Ribociclib

• Description:

  RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1][1].

• Product Name Alternative:

  LEE011

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/LEE011.html

• Purity:

  99.94

• Solubility:

  DMSO : 6.25 mg/mL (ultrasonic)

• Smiles:

  O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5

• Molecular Formula:

  C23H30N8O

• Molecular Weight:

  434.54

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21 (13) :2905-10.|[2]Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19 (22) :6173-82.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  CDK4; CDK6

• Citation 01:

  Artif Cells Nanomed Biotechnol. 2019 Dec;47 (1) :4001-4011.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Chromatogr. 2020 Mar;34 (3) :e4783.|Biomed Pharmacother. 2019 Apr:112:108602.|Biomed Res Int. 2020 Jun 11;2020:9525207.|bioRxiv. 2024 Nov 15:2024.11.11.623139.|bioRxiv. 2025 February 23.|bioRxiv. 2025 Nov 3:2025.11.02.685764.|bioRxiv. 2025 Sep 15.|Breast Cancer Res. 2019 Dec 26;21 (1) :150.|Cancer Cell. 2024 Aug 27:S1535-6108 (24) 00305-2.|Cancer Discov. 2024 Mar 1;14 (3) :446-467.|Cancer Res. 2019 Oct 15;79 (20) :5245-5259.|Cancer Res. 2025 Apr 3;85 (7) :1297-1309.|Cancers (Basel) . 2022 Nov 8;14 (22) :5481.|Cancers. 2020 Jun 16;12 (6) :1596.|Cell Chem Biol. 2019 Aug 15;26 (8) :1067-1080.e8. |Cell Chem Biol. 2025 Apr 17;32 (4) :556-569.e24.|Cell Death Dis. 2020 Sep 15;11 (9) :754.|Cell Rep Med. 2023 Oct 17;4 (10) :101200.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2017 Oct 31;21 (5) :1386-1398.|Cell Rep. 2020 Aug 4;32 (5) :107995.|Cell. 2023 Jun 8;186 (12) :2628-2643.e21.|Cell. 2025 Oct 30;188 (22) :6301-6316.e29.|Clin Cancer Res. 2015 Nov 1;21 (21) :4947-59.|Clin Cancer Res. 2025 Mar 3;31 (5) :907-920.|Department of Biochemistry. 2020 Oct.|Eur J Cancer. 2018 Oct:102:10-22.|Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Eur J Pharmacol. 2025 Sep 15:1003:177942.|Front Oncol. 2022 Apr 8;12:819003.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Harvard Medical School LINCS LIBRARY|Int J Biol Macromol. 2024 Dec 27:139117.|Int J Biol Sci. 2019 Jan 1;15 (3) :522-532. |J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 15;1147:122142.|J Infect Dis. 2018 Nov 22;218 (suppl_5) :S365-S387.|J Pharm Biomed Anal. 2021 Apr 15:197:113933.|J Transl Med. 2022 May 13;20 (1) :217.|J Virol. 2023 Jun 29;97 (6) :e0037023.|Leuk Res. 2022 Sep:120:106920.|Mil Med Res. 2022 Dec 19;9 (1) :71.|Mol Cancer Ther. 2018 May;17 (5) :897-907.|Mol Cell. 2017 Oct 19;68 (2) :336-349.e6.|Mol Oncol. 2017 Aug;11 (8) :1035-1049.|Nat Commun. 2021 Sep 10;12 (1) :5386.|Nat Commun. 2022 Aug 10;13 (1) :4689.|Nat Commun. 2019 Jun 28;10 (1) :2860.|Nature Cancer. 2021 Apr;2 (4) :429-443.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396 (7) :1435-1450.|NPJ Precis Oncol. 2021 Mar 19;5 (1) :20.|NPJ Precis Oncol. 2025 May 27;9 (1) :156.|Patent. US20220354911A1.|Pharmaceutics. 2025 Jul 25;17 (8) :967.|PLoS One. 2022 Dec 22;17 (12) :e0279522.|PLoS One. 2024 Aug 28;19 (8) :e0309289.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Research Square Print. November 7th, 2022|RSC Adv. 2020, 10 (38) :22668-22683.|Sci Adv. 2022 Dec 23;8 (51) :eadc8911.|Sci Rep. 2021 Mar 8;11 (1) :5374.|Sci Rep. 2022 Jul 20;12 (1) :12420.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Texas Southern University. 2024 July 02.|Transl Oncol. 2024 Aug 16:49:102092.|University of Innsbruck. 2025.|University of Jena. 2025.|Biochem Pharmacol. 2025 Jan 9:116744.|bioRxiv. 2023 Sep 16:2023.09.15.554413.|Clin Cancer Res. 2015 Nov 1;21 (21) :4947-59.|JCI Insight. 2022 Feb 8;7 (3) :e154402.|Cell Chem Biol. 2018 Feb 15;25 (2) :135-142.e5.|Int J Mol Med. 2025 Nov;56 (5) :167.|Nat Commun. 2021 Aug 25;12 (1) :5112.

• CAS Number:

  [1211441-98-3]